Opus Genetics, Inc.

0 products tracked · names used in filings: Opus Genetics, Inc.

Upcoming milestones

No upcoming milestones listed.

Recent milestones

Sat 17 Oct 2026🇺🇸 PDUFA datecompany-announced

Phentolamine Ophthalmic Solution 0.75%: PDUFA target action date (presbyopia)

Opus Genetics, Inc. (IRD); phentolamine; sNDA; status: set; "…The FDA accepted the Company’s supplemental New Drug Application (sNDA) for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia and set a PDUFA action date of October 17, 2026."; filed 2026-03-10 · source

Products

No products recorded.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.